Compare Lam Research Corporation (LRCX) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lam Research Corporation vs Philip Morris International Inc. — how do they compare? Lam Research Corporation trades at $318.84 (market cap $401.19B), while Philip Morris International Inc. trades at $201.19 (market cap $312.50B). The key difference: Lam Research Corporation is the larger of the two by market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Lam Research Corporation for 60 Days and Philip Morris International Inc. for 85 Days on average.
| LRCX | PM | |
|---|---|---|
Market Cap | $401.19B | $312.50B |
Volume | 8,960,892 | 5,517,172 |
Sector | Technology | Consumer Staples |
52-Week High | $433.33 | $201.19 |
52-Week Low | $131.37 | $144.33 |
Typical Hold Time | 60 Days | 85 Days |
Enterprise Value | $399.35B | $355.62B |
Dividend Yield | 0.41% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $320.59, down 2.71% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $2.18. Revenue grew to $18.44B in 2025, with a net income margin of 31.27%, while valuation ratios like P/E of 55.66 and P/S of 17.4 reflect high growth expectations. Analyst consensus is strongly bullish with a $375.68 price target, supported by AI-driven demand for semiconductor equipment.
The outlook for LRCX is positive due to robust earnings growth and strategic positioning in AI infrastructure, though risks include high valuation multiples and semiconductor cycle volatility. Upside potential exists if the company meets Q3 2026 earnings expectations and maintains margin expansion, but investors should monitor competitive pressures and macroeconomic factors affecting tech spending.
Philip Morris International (PM) trades at $200.5, up 4.05% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations, and revenue growth is robust, driven by smoke-free products like IQOS and ZYN. The stock is near its pivot point of $200, with support at $197 and resistance at $203. Cash flow trends show improving operational performance, though debt levels remain elevated.
The outlook is positive due to earnings momentum and smoke-free product expansion, but risks include regulatory pressures and high valuation. Wall Street consensus is bullish with a $212.17 price target, suggesting upside potential. Investors should weigh growth prospects against macroeconomic and industry-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
